Global Bipolar Disorder Industry

143 views

Published on

This report analyzes the worldwide markets for Bipolar Disorder in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories, Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica, Inc., Parent Company Profile - Johnson and Johnson Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer, Inc., Repligen Corporation, and Validus Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

  • Be the first to comment

  • Be the first to like this

Global Bipolar Disorder Industry

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Global Bipolar Disorder IndustryPublished on June 2010 Report SummaryThis report analyzes the worldwide markets for Bipolar Disorder in US$ Million. The report provides separate comprehensive analyticsfor the US, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006through 2015. The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc.,AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company,Forest Laboratories, Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica, Inc., ParentCompany Profile - Johnson and Johnson Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer, Inc., Repligen Corporation,and Validus Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profilesare mostly extracted from URL research and reported select online sources. Table of ContentBIPOLAR DISORDERMCP-6202A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Atypical anti-psychotics I-3 Other Therapeutics I-3II. EXECUTIVE SUMMARY 1. GLOBAL MARKET OVERVIEW II-1 Bipolar Disorder Facts II-1 A Market with Unmet Medical Needs II-1 A Major Burden on Society II-2 Current and Future Analysis II-2 Patent Expiries Depress Market Growth II-3Global Bipolar Disorder Industry (From Slideshare) Page 1/11
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Patent Expiries of Major Bipolar Disorder Drugs II-3 Loss of Exclusivity to Continue II-3 Poor Pipeline Dims Prospects for Market Growth II-3 A Few Bright Spots II-4 Opportunities and Challenges II-4 The Clinicians Quest for The Best - Seroquel XR II-5 Children and Teens - The Targets or the Beneficiaries! II-5 Adverse Events - A Major Issue with Antipsychotics II-6 Side Effects Influence Prescription Trends II-6 2. COMPETITIVE LANDSCAPE II-7 A Market Sans Competition II-7 Bipolar Disorder Drugs Market (2009): Five Major Companies with Marketed Products II-7 Antipsychotics - The Mainstay Therapy II-7 Table 1: Leading Players in Global Antipsychotic Drugs Market (2008): Annual Sales and Market Share Breakdown for Eli Lilly, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer (includes corresponding Graph/Chart) II-8 Antidepressants II-8 Table 2: Leading Drugs in the Global Antidepressants Market (2008): Revenues and Market Share Breakdown for Effexor, Cymbalta, Lexapro, Paxil/Wellbutrin, Zoloft and Remeron (includes corresponding Graph/Chart) II-9 Antiepileptics - Prescriptions Continue Despite Warning II-9 Select Antiepileptics with Approved Bipolar Disorder Indications II-10 Table 3: Leading Players in the Global Antiepileptics Market (2008): Revenue in US$ Million and Market Share Breakdown for Pfizer, Johnson & Johnson, UCB Pharma, Abbott, GlaxoSmithKline and Others (includes corresponding Graph/Chart) II-10 3. A REVIEW OF SELECT LEADING DRUGS II-11 Abilify (Aripiprazole) II-11 Geodon/Zeldox (Ziprasidone) II-11 Invega (Paliperidone) II-11 Lamictal (Lamotrigine) II-11 Risperdal (Risperidone) II-12 Risperdal® Consta® (Risperidone) II-12 Saphris (Asenapine) II-13 Seroquel (Quetiapine) II-13 Seroquel XR II-13 Zyprexa (Olanzapine) II-14 Other Drugs II-14 Depakine (Sodium Valproate) II-14 Depakote/ Depakote ER (Divalproex Sodium) II-15Global Bipolar Disorder Industry (From Slideshare) Page 2/11
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Tegretol (Carbamazepine) II-15 4. PIPELINE ANALYSIS II-16 A Few Battle Big Challenges II-16 Drug Development Pipeline for Select Bipolar Disorder Candidates II-16 Bipolar Disorder Drugs (2009) -Select Companies with Products in Late Stage Clinical Development (Phase II, III, Pending Approvals) II-17 A Review of Select Leading Pipeline Candidates II-17 Lurasidone (SM-13,496) II-17 Zomaril II-17 Nuvigil (armodafinil) II-17 RG2417 (Uridine) II-17 RGH-188 (Cariprazine) II-18 AZ - 004 (Staccato Loxapine) II-18 Lu AA39959 II-18 Lu AA34893 II-18 5. DISEASE OVERVIEW II-19 Introduction II-19 History II-19 Causes of Bipolar Disorder II-20 Triggers II-20 Episodes in a Bipolar Disorder II-21 Classification of Bipolar Disorder II-21 Bipolar Disorder Classification II-21 Symptoms of Various Types of Bipolar Disorder II-21 Mania II-21 Hypomania II-22 Mixed State II-22 Depression II-22 Additional Symptoms of Bipolar Episode II-23 Treatment of Bipolar Disorder II-23 Psychosocial Treatments II-24 Hospitalization for Extreme Cases II-24 6. CLINICAL TRIALS II-25 Cephalon Announces Promising Phase II Clinical Results of NUVIGIL II-25 Repligen Commences Phase IIB Trial of RG2417 II-25 Forest and Gedeon Richter Announce Favorable Phase II Results for Cariprazine II-25 Alexza Commences Preliminary Phase 3 Trail with Staccato® Loxapine II-26 Dainippon Sumitomo to Conduct Clinical Study for Lurasidone II-26 7. PRODUCT APPROVALS AND LAUNCHES II-27 AstraZeneca Introduces Seroquel XR® in North America II-27 AstraZeneca Introduces Seroquel XR in Europe II-27Global Bipolar Disorder Industry (From Slideshare) Page 3/11
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Wockhardt to Roll Out Divalproex ER Tablets II-27 FDA Approves SEROQUEL for Paediatric Treatment of Schizophrenia and Bipolar Disorder II-27 FDA Approves Eli Lillys Zyprexa for Schizophrenia and Bipolar Indications II-28 Pfizer Canada Receives Approval from Health Canada for ZELDOX II-28 Ortho-McNeil-Janssen Receives FDA Approval for RISPERDAL® CONSTA® II-28 FDA Grants Approval to Eurand for EUR-1048 II-28 Merck/Schering-Plough Receives EMEA Approval for SYCREST® II-29 FDA Approves SAPHRIS(R) for Treatment of Mixed/Manic Episodes of Bipolar Disorder and for Acute Treatment of Schizophrenia in Adults II-29 FDA Grants Marketing Approval to Glenmark for Lithium Carbonate Capsules II-29 Ranbaxy Australia Receives Approval from Therapeutic Goods Administration II-29 Servier Obtains Approval for Valdoxan®/Thymanax® II-29 Pfizer Canada Receives Approval from Health Canada for ZELDOX Drug II-30 Pfizer Obtains Extended Approval for Geodon II-30 FDA Considers Approval of Psychiatric Medications for Children II-30 FDA Weighs Zyprexa for Two Juvenile Indications II-30 Caraco Pharmaceutical Introduces Divalproex Sodium Delayed Release Tablets II-31 BMS and Otsuka Obtain European Marketing Approval for ABILIFY® for Manic Episodes II-31 ABILIFY® Obtains Extended Indications in Schizophrenia and Bipolar I Disorder II-31 AstraZeneca Receives European MRP Approval for SEROQUEL and SEROQUEL XR II-32 FDA Approves Seroquel XR® Extended Release Tablets II-32 Mylan Pharmaceuticals Receives FDA Approval for Risperidone Tablets USP II-32 Depakote Generic Drug Receives FDA Approval II-32 Noven Pharmaceuticals Receives FDA Approval for Stavzor II-33 BMS and Otsuka Receive FDA Approval for ABILIFY® II-33 Lupin Obtains FDA Approval for Divalproex Sodium Delayed- Release Tablets II-33 Orchid Chemicals Obtains FDA Approval for Divalproex Sodium Delayed II-33 Noven Pharmaceuticals Receives FDA Approval for Stavzor Capsules II-33 Sun Pharmaceutical Industries Receives USFDA Approval for Depakote Divalproex Sodium Tablets II-34 8. RECENT INDUSTRY ACTIVITY II-35 Abbott Takes Over Solvay Pharmaceuticals II-35 Merck & Co. Merges with Schering-Plough II-35 Pfizer Acquires Wyeth II-35Global Bipolar Disorder Industry (From Slideshare) Page 4/11
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Hisamitsu Pharmaceutical and Hisamitsu U.S. Take Over Noven Pharmaceuticals II-35 Avacta Group Acquires TheraGenetics II-36 BMS and Otsuka Extend their Agreement on Ability II-36 ADA Technologies to Develop Home Lithium-Monitor for Bipolar Disorder II-36 Repligen Licenses Global Rights for Bipolar Disorder Treatment II-36 SUN Pharmaceutical Industries to Divest Assets and Rights of Generic Drugs II-37 AstraZeneca Signs Agreement with Abraxis BioScience II-37 Roche Holding to Acquire Memory Pharmaceuticals II-37 Scientists Find Common Genetic Profile between BPD and Schizophrenia II-37 Wyeth Terminates Bifeprunox Accord with Solvay II-37 Noven Pharmaceuticals Takes Over JDS Pharmaceuticals II-38 9. FOCUS ON SELECT GLOBAL PLAYERS II-39 Abbott Laboratories, Inc. (US) II-39 AstraZeneca PLC (UK) II-39 Bristol-Myers Squibb Company (US) II-39 Cephalon, Inc. (USA) II-40 Dainippon Sumitomo Pharma Co. Ltd. (Japan) II-40 Eli Lilly and Company (US) II-41 Table 4: Eli Lillys Leading Products (2009): Global Revenues in US$ Billion by Product - Zyprexa, Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and Humulin (includes corresponding Graph/Chart) II-42 Forest Laboratories, Inc. (US) II-42 Gedeon Richter PLC (Hungary) II-42 GlaxoSmithKline PLC (UK) II-43 H. Lundbeck A/S (Denmark) II-43 Janssen Pharmaceutica, Inc. (US) II-43 Parent Company Profile - Johnson and Johnson Company (US) II-44 Merck & Co., Inc. (US) II-44 Otsuka America Pharmaceutical Inc. (US) II-45 Pfizer, Inc. (US) II-45 Repligen Corporation (US) II-45 Validus Pharmaceuticals, Inc. (US) II-46 10. GLOBAL MARKET PERSPECTIVE II-47 Table 5: World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Geographic Region - US, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) II-47 Table 6: World 10-Year Perspective for Bipolar Disorder Drugs by Geographic Region - Percentage Breakdown of Dollar SalesGlobal Bipolar Disorder Industry (From Slideshare) Page 5/11
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart) II-48 Table 7: World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Therapeutic Class - Atypical Anti-Psychotics, and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) II-49 Table 8: World 10-Year Perspective for Bipolar Disorder Drugs by Therapeutic Class - Percentage Breakdown of Dollar Sales for Atypical Anti-Psychotics, and Other Therapeutics for Years 2006, 2009, and 2015 II-49III. MARKET 1. THE UNITED STATES III-1 A.Market Analysis III-1 Current and Future Analysis III-1 Bipolar Disorder Facts III-1 Major Trends III-1 Mental Healthcare Expenditure Rising in the US III-1 Antidepressants Grow as First-line Therapy for New Patients III-2 Treatment for Bipolar Disorder Differs Based on Physician Specialty III-2 American Children Prescribed More Psychotropic Drugs than European Children III-3 Product Launches III-3 Drug Approvals III-4 Strategic Corporate Developments III-9 Key Players III-12 Abbott Laboratories, Inc. III-12 Bristol-Myers Squibb Company III-12 Eli Lilly and Company III-13 Table 9: Eli Lillys Leading Products (2009): Breakup of Global Revenues in US$ Billion by Product - Zyprexa, Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and Humulin (includes corresponding Graph/Chart) III-14 Forest Laboratories, Inc. III-14 Janssen Pharmaceutica, Inc. III-14 Merck & Co., Inc. III-15 Otsuka America Pharmaceutical, Inc. III-15 Pfizer, Inc. III-16 Repligen Corp. III-16 Validus Pharmaceuticals, Inc. III-16 B.Market Analytics III-17Global Bipolar Disorder Industry (From Slideshare) Page 6/11
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table 10: US Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-17 2. EUROPE III-18 A.Market Analysis III-18 Current and Future Analysis III-18 Product Launch III-18 Drug Approvals III-18 B.Market Analytics III-20 Table 11: European Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Geographic Region - France, Germany, Italy, the UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-20 Table 12: European 10-Year Perspective for Bipolar Disorder Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, the UK, Spain, and Rest of Europe Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart) III-21 2A. FRANCE III-22 A.Market Analysis III-22 Current and Future Analysis III-22 B.Market Analytics III-22 Table 13: French Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-22 2B. GERMANY III-23 A.Market Analysis III-23 Current and Future Analysis III-23 B.Market Analytics III-23 Table 14: German Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-23 2C. ITALY III-24 A.Market Analysis III-24 Current and Future Analysis III-24 B.Market Analytics III-24 Table 15: Italian Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ MillionGlobal Bipolar Disorder Industry (From Slideshare) Page 7/11
  8. 8. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! for Years 2006 through 2015 (includes corresponding Graph/Chart) III-24 2D. THE UNITED KINGDOM III-25 A.Market Analysis III-25 Current and Future Analysis III-25 Treatment Overview III-25 List of Licensed Drugs for Bipolar Disorder Treatment III-25 Lithium and Valproate Semisodium - Prescription Trends III-26 Strategic Corporate Development III-26 Key Players III-26 AstraZeneca PLC III-26 GlaxoSmithKline PLC III-27 B.Market Analytics III-27 Table 16: The UK Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-27 2E. SPAIN III-28 A.Market Analysis III-28 Current and Future Analysis III-28 B.Market Analytics III-28 Table 17: Spanish Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-28 2F. REST OF EUROPE III-29 A.Market Analysis III-29 Current and Future Analysis III-29 Key Players III-29 Gedeon Richter PLC (Hungary) III-29 H. Lundbeck A/S (Denmark) III-29 B.Market Analytics III-30 Table 18: Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-30 3. ASIA-PACIFIC III-31 A.Market Analysis III-31 Current and Future Analysis III-31 Australia III-31 Bipolar Disorder Facts III-31 Product Approval III-32 B.Market Analytics III-32 Table 19: Asia-Pacific Recent Past, Current & FutureGlobal Bipolar Disorder Industry (From Slideshare) Page 8/11
  9. 9. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-32 4. REST OF WORLD III-33 A.Market Analysis III-33 Current and Future Analysis III-33 Product Approval III-33 Key Player III-33 Dainippon Sumitomo Pharma Co. Ltd. (Japan) III-33 B.Market Analytics III-34 Table 20: Rest of World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart) III-34IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 53 (including Divisions/Subsidiaries - 64) ------------------------------------------ Region/Country Players ------------------------------------------ The United States 35 Canada 2 Japan 4 Europe 16 France 3 Germany 1 The United Kingdom 4 Rest of Europe 8 Asia-Pacific (Excluding Japan) 5 Middle East 2 ------------------------------------------Global Bipolar Disorder Industry (From Slideshare) Page 9/11
  10. 10. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Global Bipolar Disorder Industry Product Formats Please select the product formats and the quantity you require. 1 User License--USD 3 950.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Global Bipolar Disorder Industry (From Slideshare) Page 10/11
  11. 11. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Global Bipolar Disorder Industry (From Slideshare) Page 11/11

×